Seyahi E, Ozdogan H, Celik S, Ugurlu S, Yazici H
Division of Rheumatology, Department of Medicine, Cerrahpasa Medical Faculty, University of Istanbul, Istanbul, Turkey.
Clin Exp Rheumatol. 2006 Sep-Oct;24(5 Suppl 42):S99-103.
Regular colchicine treatment cannot control the typical febrile attacks of FMF in about 5-10% of the compliant patients. Here we report the effect of thalidomide and etanercept in 5 colchicine-resistant cases.
Five (4M/ 1F) FMF patients between April 2005 and March 2006, who were experiencing at least 2 attacks per month, despite regular colchicine were included to the study. Four male patients were given thalidomide 100 mg/d initially. Two of these patients unresponsive to thalidomide were prescribed subcutaneous injections of etanercept 25 mg, twice a week. The female patient received etanercept as the first choice due to potential side effects. She then had to be converted to thalidomide due to a severe injection site reaction.
The median follow up period with thalidomide and etanercept was 8 months. Both thalidomide and etanercept lowered the number of the abdominal attacks.
Thalidomide and etanercept might be effective as additional treatment in colchicine-resistant cases of FMF.
在约5%-10%依从性良好的患者中，常规秋水仙碱治疗无法控制家族性地中海热（FMF）的典型发热发作。在此，我们报告沙利度胺和依那西普对5例秋水仙碱抵抗病例的疗效。
纳入2005年4月至2006年3月期间的5例（4例男性/1例女性）FMF患者，尽管规律使用秋水仙碱，但每月仍至少发作2次。4例男性患者初始给予沙利度胺100mg/d。其中2例对沙利度胺无反应的患者改为皮下注射依那西普25mg，每周2次。由于潜在的副作用，女性患者首选依那西普。之后因严重的注射部位反应，她不得不改用沙利度胺。
使用沙利度胺和依那西普的中位随访期为8个月。沙利度胺和依那西普均降低了腹部发作的次数。
沙利度胺和依那西普可能作为FMF秋水仙碱抵抗病例的辅助治疗有效。
